

Ontario contributes \$1.7 M investment to advance life sciences innovation at Piramal Pharma's Aurora facility

September 30, 2026 | News

Piramal Pharma Solutions is investing over \$5.3 million in its Aurora drug substance facility to upgrade site infrastructure



Piramal Pharma Solutions (PPS), India-based Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma, has announced that its Aurora, Canada drug substance site has received a \$1,753,620 investment from the Ontario government through the Life Sciences Scale-Up Fund (LSSUF), enabling PPS to upgrade site infrastructure and commercialize Ontario-made health technologies for new markets.

With support from the government of Ontario, Piramal Pharma is investing \$5,314,000 to upgrade site infrastructure at their Aurora facility, strengthening Ontario's pharmaceutical manufacturing and bolstering domestic production of APIs. This project will enhance R&D and clinical API production, ensure the commercial availability of critical drug substances, and support a resilient and globally competitive life sciences industry in Ontario. The investment will create 12 new jobs and protect 183 existing positions.

First launched in 2024, the \$24 million LSSUF works in tandem with the government's Health Innovation Pathway to advance the objectives of Phase 2 of Ontario's Life Sciences Strategy and strengthen Ontario's position as a global leader in health innovation. Building on the fund's initial success, the 2026 Ontario Budget invested an additional \$24 million to support Ontario companies whose work will accelerate the adoption of innovative technologies in the health-care system and support the province's broader vision of providing connected, convenient care closer to home.